Genecast
PrivateLast Round
Series E
Oct 27, 2020
Est. Valuation
$779.3M
Total Funding Raised
$417.19M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Genecast is a biotechnology company that develops solutions for non-invasive diagnosis and monitoring of cancer.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Biotechnology, Medical Devices, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Genecast Comparables
Compare Genecast with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| HaploX | 89% | |
| Burning Rock | 89% | |
| New Genetron Holding Limited | 88% |
Genecast Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E | Oct 27, 2020 | ||||
| Corporate Funding | Jan 6, 2020 | ||||
| Series D | Oct 30, 2019 | ||||
| Series C | Feb 11, 2018 | ||||
| Corporate Funding | Nov 23, 2017 | ||||
Series B | Feb 10, 2017 |
Genecast Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| China Chengtong Fund Management Co., Ltd. | Series E |
| Loyal Valley Capital | Series C |
| Shenzhen Sangel Venture Capital | Angel |
| Hillhouse Investment | Series E |
| Co-Win Ventures | Series D |
| Huasheng Capital | Series E |
| China International Capital Corporation | Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 28, 2026
Grew 33% QoQ, from 27 to 36 employees.
- Jul 18, 2026
Grew 40% QoQ, from 25 to 35 employees.
Genecast Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Genecast's valuation, stock price, and market status.
Is Genecast a public or private company?
Genecast is a private company.
What is the current stock price of Genecast?
Genecast is a private company with no public stock price. No recent secondary market data is available.
How much is Genecast worth (valuation)?
Genecast's valuation is estimated at $779.3M based on funding round data.
Can I buy Genecast stock?
Genecast shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Genecast's last funding round?
Genecast's most recent funding round was Series E on October 26, 2020.
Who are the main investors in Genecast?
Key investors in Genecast include China Chengtong Fund Management Co., Ltd., Loyal Valley Capital, MPCi.
Will Genecast IPO soon?
No public IPO plans have been announced for Genecast.
How can I track Genecast secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Genecast's secondary market activity and sign up for updates.